A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight

The purpose of the studies is to evaluate the efficacy and safety of eloralintide in participants with moderate-to-severe obstructive sleep apnea and obesity or overweight. YDAO is a master protocol designed to support two independent studies: YSA1 and YSA2. Study YSA1 will include participants who are unable or unwilling to use Positive Airway Pressure (PAP) therapy and study YSA2 will include participants who are on PAP therapy for at least 3 months at time of screening and plan to continue PAP therapy during the study. Participants will be assigned to the Intervention-Specific Appendix (ISA) that reflects their current PAP usage. Participation in the study will last about 76 weeks.

NCT Number	NCT07369011
Lead Sponsor	Eli Lilly and Company
Conditions	Sleep Apnea, Obstructive, Obesity, Overweight
Enrollment	800 participants
Start Date	2026-02-10
Primary Completion	2028-03 (estimated)
Study Completion	2028-04 (estimated)
Updated on ClinicalTrials.gov	2026-08-06